INS and COVID-19: This finding corroborates the previous recommendations that insulin is still the most appropriate antihyperglycemic drug in critically ill patients with COVID-19 or uncontrolled hyperglycemia in non-critically ill patients hospitalized with COVID-19.[25–28]